Lenalidomide Plus Rituximab (R) in Non Follicular NHL
- Sponsor
- Gruppo Italiano Studio Linfomi
- Study ID
- NCT01830478
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Indolent Non Hodgkin Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Lenalidomide — DRUGLenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
- Rituximab — DRUGRituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
Study Details
The purpose of this study is to determine whether lenalidomide in association with rituximab is effective in the treatment of patients with indolent non follicular NHL relapsed after \>=2, but less than 4 prior lines of (immuno)chemotherapy.
Key Dates
- Start date
- Apr 30, 2009
- Status verified
- Apr 2013
- Primary completion
- Dec 31, 2010
- Completion
- Oct 31, 2014
Study Design
- Enrollment
- 44 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Lenalidomide and RituximabLenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
Primary Outcome Measure
Assess the efficacy [ Time Frame: Two weeks after the completion of Rituximab + Lenalidomide ]